IGM Financial Inc. (TSE:IGM – Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$43.75 and traded as high as C$43 ...

IGM Biosciences (NASDAQ:IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates, imvotamab and IGM-2644, in the wake of disappointing data.

Igm Biosciences (IGMS) has disclosed a new risk, in the Costs category. Igm Biosciences faces a potential risk if the anticipated financial and ...

High antibody titers of anti–citrullinated peptide antibodies, rheumatoid factor, and certain baseline factors predict RA ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on IGM Biosciences (IGMS – Research Report), with a price ...

With the Canadian market facing uncertainties due to potential tariffs and political shifts, investors are increasingly adopting a defensive stance. In this environment, dividend stocks can offer a ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on IGM Biosciences (IGMS – Research Report), with a ...

The tech sector's revenue and earnings growth rates are projected to accelerate in 2025. IGM's diversified portfolio, including mega, large, mid, and small caps, offers broad tech exposure ...

IGM Financial Inc. (TSE:IGM – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of C$43.50 and traded as high as ...

If you wish to manage your notification settings from this browser you will need to update your browser's settings for this ...